Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | GRM8 | O00222 | 2/20 | 0.53 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | GRM6 | O15303 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 3/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262988 | 1.00 | HSD17B10 (0.53) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| Hydrochloric Acid SCHEMBL4688181 | 0.98 | TDP1 (0.52) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| SCHEMBL13527786 | 0.90 | HSD17B10 (0.61) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| SCHEMBL11520882 | 0.84 | HSD17B10 (0.52) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| Oxfenicine SCHEMBL124861 | 0.81 | HSD17B10 (0.55) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| SCHEMBL4872444 | 0.81 | MAPT (0.41) | TDP1MEN1KMT2ACYP2C19GRM8 | |
| Oxfenicine SCHEMBL652186 | 0.81 | HSD17B10 (0.55) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| Oxfenicine SCHEMBL122315 | 0.81 | HSD17B10 (0.55) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| Phenylglycine SCHEMBL11576917 | 0.80 | CYP2D6 (0.56) | HSD17B10TDP1MEN1CYP2C9KMT2A | |
| Phenylglycine SCHEMBL157180 | 0.80 | CYP2D6 (0.56) | HSD17B10TDP1MEN1CYP2C9KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2665493-B1 | MRI MARKERS, DELIVERY AND EXTRACTION SYSTEMS, AND METHODS OF MANUFACTURE AND USE THEREOF | UNIV TEXAS (US) | 2018-03-21 | — | — | EP | claimed |
| CN-103450068-B | A kind of synthetic method of Ziprasidone intermediate | CHONGQING CHANGJIE MEDICAL CHEMICAL CO., LTD. (CN) | 2015-09-16 | — | — | CN | claimed |
| CN-103450068-A | Synthetic method of ziprasidone intermediate | CHONGQING CHANGJIE MEDICINE CHEMICAL CO LTD | 2013-12-18 | — | — | CN | claimed |
| CN-1068621-C | Polyimide compositions for electrodeposition and coatings formed of the same | HIROSHI ITATANI (JP) | 2001-07-18 | — | — | CN | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| CN-1154988-A | Polyimide compositions for electrodeposition and coatings formed of the same | PI MATERIALS RESEARCH LAB (JP) | 1997-07-23 | — | — | CN | claimed |
| US-20260042806-A1 | NOVEL PORE MONOMERS AND PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-02-12 | — | — | US | disclosed |
| EP-4569330-A1 | NOVEL PORE MONOMERS AND PORES | Oxford Nanopore Technologies PLC (GB) | 2025-06-18 | — | — | EP | disclosed |
| CN-119630970-A | Novel Kong Shanti and holes | 牛津纳米孔科技公开有限公司 | 2025-03-14 | — | — | CN | disclosed |
| EP-4433487-A1 | CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER | BioSight Ltd. (IL) | 2024-09-25 | — | — | EP | disclosed |
| WO-2024033443-A1 | NOVEL PORE MONOMERS AND PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-02-15 | — | — | WO | disclosed |
| CN-110621695-B | anti-JAGGED 1 antigen binding proteins | 安进公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2023089617-A1 | CYTARABINE-AMINO ACID BASED PRODRUG FOR THE TREATMENT OF CANCER | BIOSIGHT LTD. (IL) | 2023-05-25 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
| EP-0090240-A2 | 7-Alpha-aminoacyl-3-chlorocephalosporins, their preparation and their use as pharmaceutical products | BAYER AG (DE) | 1983-10-05 | — | — | EP | disclosed |
| EP-0049338-A1 | Ink for use in ink jet printing | International Business Machines Corporation (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042806-A1 | NOVEL PORE MONOMERS AND PORES | SCNN1G, CACNG3, ASIC3 | HSD17B10 4856/4885TDP1 4238/4885MEN1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.